Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single‐center validation study
In AML, the revised WT1 threshold of seven copies per 10<sup>4</sup> ABL copies enhanced MRD sensitivity while maintaining specificity, improving concordance with NPM1, and showing prognostic relevance. These findings support the clinical value of locally optimized WT1 thresholds, and highlight the need for prospective multicenter validation and harmonization of WT1-based MRD monitoring.
Authors
- Andréï Tchirkov (ORCID: https://orcid.org/0000-0002-7050-498X)
- Céline Bourgne (ORCID: https://orcid.org/0000-0002-1781-1323)
- Romain Guièze (ORCID: https://orcid.org/0000-0001-7563-580X)
- Sabrina Barrière
- Lauren Véronèse (ORCID: https://orcid.org/0000-0002-4414-7974)
- Aurélie Ravinet (ORCID: https://orcid.org/0000-0003-1228-9481)
- Marc Berger (ORCID: https://orcid.org/0000-0003-1858-0587)
- Benjamin Lebecque (ORCID: https://orcid.org/0000-0002-4890-336X)
- Inés Llamas Ramos
- Thomas Tassin (ORCID: https://orcid.org/0000-0001-9096-0109)
- Marie De Antonio (ORCID: https://orcid.org/0000-0001-5114-0546)
- Anais Establie
Institutions
- University of Clermont Auvergne (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Clermont Université (FR)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1002/cncr.70140
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00